Sugi Predict

Sugi Predict / Targets / RCOR1

RCOR1

REST corepressor 1 (Protein CoREST) · Q9UKL0 · RCOR1 on Sugi Atlas →

33,674 patent compounds predicted against RCOR1, 23,111 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1428491 SCHEMBL1428491 0.79 19/20
SCHEMBL1427844 SCHEMBL1427844 0.76 19/20
SCHEMBL1428372 SCHEMBL1428372 0.75 18/20
SCHEMBL1428110 SCHEMBL1428110 0.71 18/20
SCHEMBL1427588 SCHEMBL1427588 0.68 18/20
SCHEMBL1428116 SCHEMBL1428116 0.68 18/20
SCHEMBL1427822 SCHEMBL1427822 0.68 18/20
SCHEMBL1430373 SCHEMBL1430373 0.63 18/20
SCHEMBL1427795 SCHEMBL1427795 0.63 18/20
SCHEMBL1430305 SCHEMBL1430305 0.61 18/20
SCHEMBL1430401 SCHEMBL1430401 0.59 18/20
SCHEMBL1428207 SCHEMBL1428207 0.58 18/20
SCHEMBL1430133 SCHEMBL1430133 0.58 18/20
SCHEMBL1427800 SCHEMBL1427800 0.57 18/20
SCHEMBL1430538 SCHEMBL1430538 0.52 18/20
SCHEMBL1428346 SCHEMBL1428346 0.51 18/20
SCHEMBL1428367 SCHEMBL1428367 0.80 17/20
SCHEMBL1430691 SCHEMBL1430691 0.69 17/20
SCHEMBL1428164 SCHEMBL1428164 0.66 17/20
SCHEMBL1427723 SCHEMBL1427723 0.66 17/20

Clinical trials — most relevant to RCOR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room PHASE2/PHASE3COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) PHASE1/PHASE2COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Family Resilience Initiative Research Program nanUNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders nanNOT_YET_RECRUITING
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RCOR1 binder may also engage these)

ProteinNameSimilarity
Q8CFE3 — 1.000 Q8CFE3 →
Q6P116 — 0.997 Q6P116 →
Q6NRZ0 — 0.996 Q6NRZ0 →
Q6PGA0 — 0.994 Q6PGA0 →
Q90WN5 — 0.993 Q90WN5 →
RCOR3 REST corepressor 3 0.993 landscape →
SMARCC2 SWI/SNF complex subunit SMARCC2 0.990 landscape →
SMARCC1 SWI/SNF complex subunit SMARCC1 0.989 landscape →
P97496 — 0.989 P97496 →
B4P6P7 — 0.988 B4P6P7 →
B3MJ69 — 0.988 B3MJ69 →
A0A286Y9D1 — 0.987 A0A286Y9D1 →
O43150 — 0.987 O43150 →
ASH2L Set1/Ash2 histone methyltransferase complex subunit ASH2 0.987 landscape →
Q9D4H9 — 0.987 Q9D4H9 →
DHX29 ATP-dependent RNA helicase DHX29 0.987 landscape →
B4NBP4 — 0.987 B4NBP4 →
G5EFD2 — 0.987 G5EFD2 →
Q9V9K7 — 0.987 Q9V9K7 →
B3MSI4 — 0.987 B3MSI4 →
A1ZAB5 — 0.987 A1ZAB5 →
B3M301 — 0.987 B3M301 →
B4MY63 — 0.987 B4MY63 →
KAT8 Histone acetyltransferase KAT8 0.987 landscape →
O94880 — 0.986 O94880 →
B4GAM1 — 0.986 B4GAM1 →
Q9VVI2 — 0.986 Q9VVI2 →
Q24168 — 0.986 Q24168 →
B3MIW0 — 0.986 B3MIW0 →
Q09228 — 0.986 Q09228 →